NEONC TECHNOLOGIES HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $67.09M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | – | $-0.58 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 3, 2026 | After market close | – | $-3.20 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | – | $-0.45 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 22, 2025 | After market close | – | $-0.30 | – |
Press releases
Announcements Neonc Technologies filed with the SEC
NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc CEO Amir F. Heshmatpour to Address Global Life
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Holdings, Inc. Announces Pricing of $15
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Keithly Garnett - Chief Financial Officer, NeOnc Technologies Holdings, Inc.
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Reports Positive Topline
Regulation FD disclosure · EX-99.1 to Form 8-K
NEO100 - 01 NCT02704858: A Phase 1/2a Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 - Mutated Glioma Reporting out the Phase 2a objectives August 12, 2026
Regulation FD disclosure · EX-99.2 to Form 8-K
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion,
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by
Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Reports Q4 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Appoints David Choi as Chief
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Conference Call to Present Dose-Escalation Results from Full Phase 1
Regulation FD disclosure · EX-99.3 to Form 8-K
NeOnc Technologies (Nasdaq: NTHI) to Host Investor
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Reports Updated Clinical Results
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies (Nasdaq: NTHI) Announces
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Reports Updated Clinical Results
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Conference Call to Present Data Updates from Ongoing NEO100-1 Phase
Regulation FD disclosure · EX-99.3 to Form 8-K
Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from
Regulation FD disclosure · EX-99.1 to Form 8-K
Technologies Appoints Amir Heshmatpour as Chief Executive Officer to
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies’ Subsidiary,
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies’ Subsidiary, NeuroMENA, Signs Master Services Agreement with M42’s IROS and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar
Regulation FD disclosure · EX-99.2 to Form 8-K
NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
NeOnc Technologies Signs Definitive Agreement
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
NeOnc Technologies Executes Sub-License Agreement,
Regulation FD disclosure · EX-99.1 to Form 8-K